Research and Development
An increasing number of vitamin K and menaquinone-7 scientific studies now substantiate present use. However, still more studies are necessary in bone and cardiovascular health -- as well as in new interesting areas where vitamin K2 may be important. This implies that further research is relevant and needed. Through a long-term agreement since 2006, NattoPharma has been in a close R&D collaboration with VitaK BV, University in Maastricht, the Netherlands. To strengthen our research NattoPharma also signed in 2013 a new and long-term research agreement with the Cardiovascular Research November Institute Maastricht, (CARIM), University of Maastricht. These agreements provide NattoPharma with the option to study mechanisms of action of vitamin K2 and to further evaluate the impact of Vitamin K2 on human health.
These R&D agreements and contacts with other outstanding medical institutions enable Nattopharma to explore and strengthen NattoPharma’s present recommendations and future use of MenaQ7 products. We are proud and excited to be part of and to stimulate the Vitamin K2 research in biochemical and clinical settings.
Dr. Cees Vermeer – one of the world leading experts on Vitamin K2
Dr. Vermeer studied Biochemistry at Leiden, where he also presented his PhD thesis (1974) on the initiation of protein biosynthesis in E coli.
For futher information, please contact:
Dr. Vladimir Badmaev
Head of R&D